CAR T cell immunotherapies – Updated labeling and elimination of REMS
June 26, 2025 - The FDA approved updated labeling for currently approved BCMA- and CD19-directed autologous chimeric antigen receptor (CAR) T cell immunotherapies and eliminated the Risk Evaluation and Mitigation Strategies (REMS) program for these products.